lorazepam has been researched along with selegiline in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 7 (70.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Gao, F; Lombardo, F; Shalaeva, MY; Tupper, KA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cerza, RF | 1 |
| De Angelis, L; Furlan, C | 1 |
| Preskorn, SH | 1 |
1 review(s) available for lorazepam and selegiline
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
9 other study(ies) available for lorazepam and selegiline
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
Topics: 1-Octanol; Chromatography, High Pressure Liquid; Pharmaceutical Preparations; Solubility; Water | 2001 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Beta-selective monoamine oxidase inhibitors and cardiac anesthesia.
Topics: Aged; Aged, 80 and over; Analgesics, Opioid; Anesthetics, Inhalation; Anesthetics, Intravenous; Aortic Valve; Coronary Artery Bypass; Drug Interactions; Etomidate; Female; Heart Valve Prosthesis; Humans; Hydromorphone; Hypnotics and Sedatives; Lorazepam; Monoamine Oxidase Inhibitors; Morphine; Selegiline | 1995 |
The anxiolytic-like properties of two selective MAOIs, moclobemide and selegiline, in a standard and an enhanced light/dark aversion test.
Topics: Animals; Anti-Anxiety Agents; Behavior, Animal; Convulsants; Darkness; Drug Interactions; Female; Light; Lorazepam; Mice; Moclobemide; Monoamine Oxidase Inhibitors; Pentylenetetrazole; Selegiline | 2000 |
Multiple medication use presenting as Parkinson's dementia complex: a message from Titanic.
Topics: Aged; Anti-Infective Agents; Antiparkinson Agents; Antipsychotic Agents; Bacteriuria; Ciprofloxacin; Dementia; Drug Interactions; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Fluoxetine; Haloperidol; Hospitalization; Humans; Hypnotics and Sedatives; Lorazepam; Parkinson Disease; Psychomotor Agitation; Selegiline; Trihexyphenidyl | 2008 |